Skip to main content
CNTB logo

Connect Biopharma Holdings Limited

CNTBNASDAQHealthcareBiotechnology

$0.91Today:- (-)1Y −47.62%

As of Oct 16, 2026 close

Market cap
$56.99M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.85$3.82
Volume (live)
-
Avg. volume (3M)
7.47M

Connect Biopharma Holdings (CNTB) Cash Flow Statement

In fiscal 2025 (fiscal year ended Mar 31, 2026), Connect Biopharma Holdings used $51.21M of cash in operating activities and spent $434.00K on capital expenditures. That left free cash flow of −$51.64M.

Connect Biopharma Holdings Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Connect Biopharma Holdings Limited (CNTB) - Annual data in millions USD
BreakdownFY 2025FY 2025FY 2024FY 2024FY 2023FY 2022FY 2021FY 2021FY 2021FY 2020FY 2019
Period endingMar 2026Dec 2025Mar 2025Dec 2024Dec 2023Dec 2022Mar 2022Jan 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-55.48-55.48-15.63-15.63-59.38-116.12-204.94-202.27--119.36-24.46
Depreciation & Amortization0.700.700.660.660.721.010.640.630.630.220.11
Deferred Income Tax0.00-0.00-0.003.37106.37--89.688.30
Stock Based Compensation3.733.736.736.735.401.011.418.998.993.860.56
Change in Working Capital0.580.58-15.49-15.499.857.163.273.583.58-0.442.38
Change in Accounts Receivable0.780.78-0.79-0.791.040.000.00-2.31--1.430.00
Change in Inventory0.00-0.00-0.000.000.00--0.000.00
Change in Accounts Payable1.621.62-1.87-1.87-1.140.388.898.977.240.282.81
Change in Other Working Capital-1.82-1.82-12.830.32-2.016.78-5.62-3.080.010.71-0.43
Other Operating Activities-0.74-0.12--2.01-1.350.01104.700.0190.110.01
Net Cash from Operating Activities-51.21-51.21-23.61-23.61-47.74-99.27-85.57-84.32-84.32-25.60-13.09
Investing Activities
Capital Expenditures-0.43-0.43-0.75-0.75-0.08-4.28-7.46-3.83-7.32-2.29-0.16
Acquisitions0.00-0.00-2.940.080.05--0.050.00
Purchases of Investments-30.47-30.47-15.45-2.70-31.03-113.70-17.982.12-17.962.79-23.65
Sales/Maturities of Investments39.9540.7212.6312.75103.1534.5420.10-0.0520.08-0.0523.32
Other Investing Activities0.78-0.12--0.08-0.08-0.05-3.44--0.050.00
Net Cash from Investing Activities9.829.82-3.45-3.4574.98-83.44-5.34-5.21-5.210.45-0.48
Financing Activities
Debt Repayment0.00-0.00--0.29-0.22-0.13--0.13-0.08-0.06
Common Stock Issued1.091.090.230.230.040.02219.99220.02219.990.000.00
Common Stock Repurchased0.00-0.00-0.000.00-0.57-0.57-0.570.000.00
Other Financing Activities0.00-0.00-0.000.12-17.07-17.11-17.11-0.600.01
Net Cash from Financing Activities1.091.090.230.230.05-0.09206.66202.22202.22140.73-0.06
Summary
Effect of Forex Changes on Cash0.410.41-0.60-0.60-0.5713.87-6.34-0.22-8.180.20
Net Change in Cash-39.89-39.89-27.43-27.4326.72-168.93109.42112.91112.69107.39-13.44
Cash at Beginning of Period78.2378.23105.66105.6678.95249.30158.61-154.8047.3358.26
Cash at End of Period38.3538.3578.2378.23105.6680.37268.02-267.72154.7344.82
Free Cash Flow-51.64-51.64-24.36-24.36-47.82-103.55-93.03-88.16-91.65-27.90-13.25
Supplemental Disclosures
Income Taxes Paid-0.29-0.110.12------

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Connect Biopharma Holdings Cash Flow

What is Connect Biopharma Holdings's free cash flow?

Connect Biopharma Holdings had negative free cash flow of $51.64M in fiscal 2025 (fiscal year ended Mar 31, 2026), operating cash flow of −$51.21M minus $434.00K of capital expenditures.

How much does Connect Biopharma Holdings spend on capital expenditures?

Connect Biopharma Holdings spent $434.00K on capital expenditures in fiscal 2025, compared with $750.00K a year earlier.

Does Connect Biopharma Holdings pay dividends or buy back shares?

Connect Biopharma Holdings's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition